US EditionHigh-Dose EGFR-TKIs Plus Pemetrexed Combat NSCLC
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
High-Dose EGFR-TKIs Plus Pemetrexed Combat NSCLC
In the relentless battle against advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations (EGFRm), a recent study has illuminated a promising therapeutic avenue that could redefine management strategies for leptomeningeal metastases (LM). Researchers from the First Affiliated Hospital of Gannan Medical University have unveiled compelling evidence supporting the combined use of high-dose third-generation EG…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
